Business Context and Reporting Period
Company: Galmed Pharmaceuticals Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2026 (Unaudited)
Filing Date: July 8, 2026
Galmed is a biopharmaceutical company focused on developing Aramchol for liver disease, oncological indications, and cardiometabolic conditions. The company has no approved products and has not generated revenue from product sales. It operates with an accumulated deficit and relies on capital raises to fund operations.
Key Financial Metrics
| Metric (in thousands USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,910) | $(1,104) |
| Net Loss Per Share (Basic/Diluted) | $(0.29) | $(0.62) |
| Operating Expenses | $(2,044) | $(1,264) |
| Cash and Cash Equivalents | $1,600 | $4,000 (Dec 31, 2025) |
| Total Current Assets | $16,027 | $18,627 (Dec 31, 2025) |
| Accumulated Deficit | $(212,688) | $(201,573) (Mar 31, 2025) |
| Cash Used in Operating Activities | $(2,536) | $(1,167) |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss increased by 73% to $1.9 million, driven primarily by a 133% increase in Research and Development (R&D) expenses to $1.4 million. This was due to higher clinical trial and pre-clinical study costs.
- Liquidity Decline: Cash and cash equivalents dropped from $4.0 million at year-end 2025 to $1.6 million at March 31, 2026. Total current assets decreased by approximately $2.6 million.
- Share Count: Weighted-average shares outstanding increased significantly to 6.59 million (from 1.80 million in Q1 2025), diluting per-share loss impact despite higher absolute losses.
- Financing Activity: Unlike Q1 2025, which saw $1.5 million in financing proceeds, Q1 2026 had no financing cash flows.
Outlook, Risks, and Unusual Items
Recent Developments (Subsequent Events)
- Colospan Acquisition: On June 22, 2026, Galmed completed the acquisition of Colospan Ltd., a medical device company. Consideration included $3.3 million in cash and up to $2.0 million in performance-based earnout.
- SEPA Utilization: Subsequent to the balance sheet date, the company sold 1,361,000 shares under its Standby Equity Purchase Agreement (SEPA) for net proceeds of approximately $1.2 million.
Liquidity and Going Concern
Management estimates current cash resources will support operations for more than 12 months. However, the company explicitly states it will need substantial additional capital to fund R&D and commercialization. Failure to secure funding could raise substantial doubt about its ability to continue as a going concern.
Risks
- Regulatory approval uncertainty for Aramchol.
- Integration risks associated with the Colospan acquisition.
- Security and economic instability in the Middle East/Israel.
- Dependence on future equity or debt financing.
Investor Verification Checklist
- Cash Runway: Verify if the $1.2 million SEPA proceeds (post-period) and existing $15.6 million in liquid assets are sufficient to cover the increased burn rate post-acquisition.
- Acquisition Impact: Review the specific terms of the Colospan earnout and how the $3.3 million cash outflow impacts immediate liquidity.
- R&D Milestones: Confirm the specific clinical trial phases driving the 133% increase in R&D spend and expected timelines for results.
- Financing Capacity: Assess the remaining capacity under the SEPA ($20M commitment) and the ATM facility ($8.1M commitment) to fund future operations.